Previous Close | 0.8602 |
Open | 0.8310 |
Bid | 0.8003 x 1100 |
Ask | 0.8455 x 1400 |
Day's Range | 0.8310 - 0.8597 |
52 Week Range | 0.4100 - 1.1200 |
Volume | |
Avg. Volume | 1,643,645 |
Market Cap | 156.075M |
Beta (5Y Monthly) | 0.86 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.4500 |
Earnings Date | May 07, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 2.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for NKTR
The placebo-controlled, phase IIb study will investigate the efficacy and safety of Nektar's (NKTR) rezpeg in patients with severe to very severe alopecia areata.
Nektar (NKTR) reports a wider-than-expected loss in the fourth quarter of 2023 while revenue beat estimates.
Nektar Therapeutics (NASDAQ:NKTR) Q4 2023 Earnings Call Transcript March 4, 2024 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.22 EPS, expectations were $-0.2. NKTR isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and thank you for […]